| Autor: |
Lipe DN; ProPharma Group, Raleigh, NC 27601, USA., Qdaisat A; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Krishnamani PP; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nguyen TD; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Chaftari P; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., El Messiri N; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Srinivasan A; Department of Cardiology, HCA Houston Kingwood, College of Medicine, University of Houston, Kingwood, TX 77339, USA., Galvis-Carvajal E; Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Reyes-Gibby CC; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wattana MK; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. |
| Abstrakt: |
Immune checkpoint inhibitors (ICIs) have significantly transformed cancer treatment, but their use is linked to immune-related adverse events (irAEs), including the rare ICI-associated myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome. This systematic review aims to highlight MMM's clinical implications in emergency departments. PubMed and Embase were searched using a specific search strategy. Reports were eligible for inclusion if all three conditions were present and associated with the use of an ICI. Data were extracted by independent reviewers using the Rayyan web application for systematic reviews. Descriptive statistics and qualitative synthesis were used to summarize demographic, clinical, and treatment data for the reported cases. Among 50 cases, predominantly associated with melanoma, lung cancer, and renal cancer, the in-hospital mortality rate was 38.0%. The most commonly presenting symptoms were ptosis (58%), dyspnea (48%), diplopia (42%), or myalgia (36%). The median time from ICI initiation to MMM presentation was 21 days (interquartile range: 15-28 days). Corticosteroids were the primary treatment for the irAEs. MMM, a rare but potentially fatal complication of ICI therapy, requires prompt recognition in emergency settings. Corticosteroids should be initiated if suspected, without waiting for confirmation. Multidisciplinary collaboration is vital for diagnosis and treatment planning. Research on MMM's link to specific cancers and ICIs is imperative for better risk assessment and interventions. |
